D. E. Shaw & Co., Inc. Puma Biotechnology, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 640,780 shares of PBYI stock, worth $3.31 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
640,780
Previous 571,665
12.09%
Holding current value
$3.31 Million
Previous $1.69 Million
29.85%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding PBYI
# of Institutions
126Shares Held
33.3MCall Options Held
68.2KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$21.3 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$19.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$18.4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.01MShares$10.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.87MShares$9.67 Million0.01% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $235M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...